Literature DB >> 1150527

Lipiarmycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies.

F Parenti, H Pagani, G Beretta.   

Abstract

The producer strain of the new antibiotic, lipiarmycin, is described. The colony morphology, the presence of globose sporangia bearing motile spores, the absence of aerial mycelium and the presence of meso-DAP in cell wall, ascribe this strain to the genus Actinoplanes. The pigmentation and morphological characteristics together with the cultural and physiological features distinguish this strain from all the described Actinoplanes species. It is considered to be a new species for which the name Actinoplanes deccanensis nov. sp. is proposed. Lipiarmycin is produced in an organic complex medium containing NaCl. Production occurs at the end of trophophase and continues, though at decreasing rate, during isophase.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1150527     DOI: 10.7164/antibiotics.28.247

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  18 in total

Review 1.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

2.  Bioactive compounds from marine actinomycetes.

Authors:  Renu Solanki; Monisha Khanna; Rup Lal
Journal:  Indian J Microbiol       Date:  2009-01-08       Impact factor: 2.461

Review 3.  Natural Products as Platforms To Overcome Antibiotic Resistance.

Authors:  Sean E Rossiter; Madison H Fletcher; William M Wuest
Journal:  Chem Rev       Date:  2017-09-27       Impact factor: 60.622

Review 4.  Astonishing diversity of natural surfactants: 2. Polyether glycosidic ionophores and macrocyclic glycosides.

Authors:  Valery M Dembitsky
Journal:  Lipids       Date:  2005-03       Impact factor: 1.880

Review 5.  Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Authors:  Kathleen Mullane
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

6.  In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile.

Authors:  R N Swanson; D J Hardy; N L Shipkowitz; C W Hanson; N C Ramer; P B Fernandes; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

7.  Lipiarmycin-resistant ribonucleic acid polymerase mutants of Bacillus subtilis.

Authors:  A L Sonenshein; H B Alexander; D M Rothstein; S H Fisher
Journal:  J Bacteriol       Date:  1977-10       Impact factor: 3.490

Review 8.  New target for inhibition of bacterial RNA polymerase: 'switch region'.

Authors:  Aashish Srivastava; Meliza Talaue; Shuang Liu; David Degen; Richard Y Ebright; Elena Sineva; Anirban Chakraborty; Sergey Y Druzhinin; Sujoy Chatterjee; Jayanta Mukhopadhyay; Yon W Ebright; Alex Zozula; Juan Shen; Sonali Sengupta; Rui Rong Niedfeldt; Cai Xin; Takushi Kaneko; Herbert Irschik; Rolf Jansen; Stefano Donadio; Nancy Connell; Richard H Ebright
Journal:  Curr Opin Microbiol       Date:  2011-08-19       Impact factor: 7.934

Review 9.  Actinomycetes: A Never-Ending Source of Bioactive Compounds-An Overview on Antibiotics Production.

Authors:  Davide De Simeis; Stefano Serra
Journal:  Antibiotics (Basel)       Date:  2021-04-22

10.  Structural Basis of Transcription Inhibition by Fidaxomicin (Lipiarmycin A3).

Authors:  Wei Lin; Kalyan Das; David Degen; Abhishek Mazumder; Diego Duchi; Dongye Wang; Yon W Ebright; Richard Y Ebright; Elena Sineva; Matthew Gigliotti; Aashish Srivastava; Sukhendu Mandal; Yi Jiang; Yu Liu; Ruiheng Yin; Zhening Zhang; Edward T Eng; Dennis Thomas; Stefano Donadio; Haibo Zhang; Changsheng Zhang; Achillefs N Kapanidis; Richard H Ebright
Journal:  Mol Cell       Date:  2018-03-29       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.